Trial Profile
Phase I/II study of AF802 in patients with Non-Small Cell Lung Cancer harboring ALK fusion gene
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 25 Jun 2018
Price :
$35
*
At a glance
- Drugs Alectinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 18 Oct 2017 Final efficacy and safety results of phase II part of study (n=46), presented at the 18th World Conference on Lung Cancer.
- 15 Mar 2017 Results of three year follow-up data of phase II part of this study (n=46) published in the Journal of Clinical Oncology
- 02 Jun 2015 Results of the phase II portion presented at the 51st Annual Meeting of the American Society of Clinical Oncology.